Anixa Biosciences, Inc. is developing therapies and vaccines that are focused on critical unmet needs in oncology. Anixa’s programs are using the body’s immune system to take multiple approaches in fighting cancer—CAR-T cell therapy to treat cancer and vaccines to prevent cancer.
Therapeutics
We are developing chimeric antigen receptor T-cell (CAR-T) based immuno-therapy drugs which genetically engineer a patient’s own immune cells to fight cancer.
Vaccines
We are developing a revolutionary vaccine technology focused on preventing breast cancer, specifically triple negative breast cancer, the most lethal form of the disease.
Using a similar mechanism of action as our breast cancer vaccine technology, we are developing a vaccine to prevent the occurrence of ovarian cancer.
Lung, Colon, & Prostate Cancer Vaccines
We have commenced a cancer vaccine discovery program utilizing the same mechanism as our breast and ovarian cancer vaccines, to develop additional cancer vaccines to address many intractable cancers, including high incidence malignancies in lung, colon, and prostate.
Latest News & Events
Anixa Biosciences Announces FDA Approval of Individual Patient IND for its Ovarian Cancer CAR-T Therapy
Read More...Anixa Biosciences Announces Japanese Patent on Breast Cancer Vaccine Technology
Read More...Anixa Biosciences Announces $5 Million Share Repurchase Program
Read More...